Stephanie McTighe, PhD, Director, Pharmacology

As a member of the pharmacology team, Stephanie provides quantitative understanding for Arkuda’s lead molecules. She works closely with the biology team to develop models that evaluate the potential therapeutic utility of Arkuda’s neurodegeneration drug candidates. Prior to joining Arkuda she served as head of in vivo pharmacology at Sage Therapeutics. Stephanie is excited by the potential of targeting lysosomal biology to provide meaningful treatments for multiple neurodegenerative conditions. She received her PhD at the University of Cambridge and completed a postdoctoral fellowship at Pfizer, where she worked on mouse models of neurodevelopmental disorders.